Latest California Healthline Stories
Florida Sen. Rick Scott Off Base in Claim That Rise in Medicare Premiums Is Due to Inflation
The Republican senator says President Joe Biden’s “inflation crisis” caused Medicare to raise monthly premiums, which will add hundreds of dollars to beneficiaries’ costs. But Medicare experts say inflation was not to blame and most beneficiaries will shoulder a much smaller increase than what Rick Scott claims.
KHN’s ‘What the Health?’: The Big Biden Budget Bill Passes the House
President Joe Biden’s social spending budget is on its way to the U.S. Senate, where Democratic leaders are (optimistically) hoping to complete work by the end of the year. Meanwhile, covid is surging again in parts of the country, along with the political divides it continues to cause. Margot Sanger-Katz of The New York Times, Joanne Kenen of Politico and the Johns Hopkins School of Public Health, and Mary Agnes Carey of KHN join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner previews next week’s Supreme Court abortion oral arguments with Florida State University law professor Mary Ziegler.
Why You Can’t Find Cheap At-Home Covid Tests
You probably won’t be testing everyone at your Thanksgiving table for covid because the tests are expensive and hard to find. Why? The federal government is partly to blame.
Vaccine-or-Test Requirements Increase Work and Costs for Governments
But state and local officials embrace the requirement because it creates a safer workplace while allowing employees to continue working.
KHN’s ‘What the Health?’: Boosting Confusion
Federal health officials appear poised to extend a recommendation for covid boosters to all adults, following moves by some governors and mayors to broaden the eligible booster pool as caseloads rise. Meanwhile, the Food and Drug Administration finally has a nominee to head the agency: former FDA chief Robert Califf. And Medicare premiums for consumers will likely rise substantially in 2022, partly due to the approval of a controversial drug to treat Alzheimer’s disease. Tami Luhby of CNN, Sarah Karlin-Smith of the Pink Sheet and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Dan Weissmann, host of the “An Arm and a Leg” podcast.
Congressional Doctors Lead Bipartisan Revolt Over Policy on Surprise Medical Bills
Congress last year shielded consumers from unexpected out-of-network charges, but hospitals and doctors have decried the arbitration plan put forward by the Biden administration for negotiating these bills as favoring insurers. More than 150 members of the House agree.
KHN’s ‘What the Health?’: Why Health Care Is So Expensive, Chapter $22K
Congress is making slow progress toward completing its ambitious social spending bill, although its Thanksgiving deadline looks optimistic. Meanwhile, a new survey finds the average cost of an employer-provided family plan has risen to more than $22,000. That’s about the cost of a new Toyota Corolla. Alice Miranda Ollstein of Politico, Anna Edney of Bloomberg News and Rebecca Adams of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Rebecca Love, a nurse academic and entrepreneur, about the impending crisis in nursing.
‘Drinking Through a Lead Straw’ — $15B Approved to Fix Dangerous Water Pipes
The infrastructure bill passed Friday funnels $15 billion into lead pipe remediation. Water quality experts say the cost of getting rid of all lead pipes could ultimately cost $60 billion. Still, some health advocates say the new funding will be transformative in allowing communities such as Houston’s Fifth Ward to fix its pipes.
Democrats Plan to Expand Medicare Hearing Benefits. What Can Consumers Expect?
KHN answers questions for seniors about how this new benefit might work.
Despite Restraints, Democrats’ Drug Pricing Plan Could Still Aid Consumers
A last-minute agreement among lawmakers restored a provision seeking to hold down rising costs of prescription medicines. Although details on which drugs will be targeted remain sketchy, the legislation would help patients buying insulin and cap Medicare beneficiaries’ out-of-pocket drug costs at $2,000 a year.